Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) has appointed Dr. Stephen L. Mayo, a distinguished protein engineering expert, to its Board of Directors effective immediately. Dr. Mayo, who currently holds a professorship at Caltech and serves on Merck's board, brings extensive scientific knowledge and business insights. The leadership highlights that Dr. Mayo's expertise will enhance Sarepta's capabilities as it advances its gene therapy pipeline. This strategic addition aims to bolster the company's position in genetic medicine for rare diseases.
Sarepta Therapeutics (SRPT) reported a 37% increase in net product sales for Q3 2021, totaling $166.9 million. Due to strong performance, the company raised its full-year guidance by $40 million, now projecting revenues of $605-$615 million. This marks the 20th consecutive quarter of revenue growth. Sarepta launched two pivotal trials for its therapies targeting Duchenne muscular dystrophy and presented promising data for its gene therapy programs. The company ended Q3 with over $2 billion in cash and equivalents, positioning it for future development.
Sarepta Therapeutics (NASDAQ:SRPT) announced participation in three virtual investor conferences. Senior management will engage in fireside chats at:
- Credit Suisse 30th Annual Healthcare Conference on November 9, 2021 at 12:10 p.m. E.T.
- Barclays Gene Editing & Gene Therapy Summit on November 15, 2021 at 3:00 p.m. E.T.
- Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021 at 1:25 p.m. E.T.
Webcasts will be available on Sarepta’s website, archived for 90 days. The company focuses on precision genetic medicine for rare diseases.
Sarepta Therapeutics (NASDAQ:SRPT) announced on October 29, 2021, equity awards for 17 newly hired employees as part of its 2014 Employment Commencement Incentive Plan. The total awards include options to purchase 15,025 shares and 7,975 restricted stock units (RSUs). The exercise price of the options is set at $79.13 per share, aligned with the stock's closing price on the grant date. Options will vest over four years, while RSUs will vest annually over the same period, contingent on continued employment.
Sarepta Therapeutics (NASDAQ:SRPT) is set to report its third quarter 2021 financial results on November 3, 2021, after the market closes. A conference call will follow at 4:30 p.m. E.T. to discuss financial results and provide corporate updates. Investors can access the call by dialing (844) 534-7313 for domestic calls or (574) 990-1451 internationally, using passcode 7131019. The call will also be available via live webcast on the company's investor relations website and archived for 90 days.
Sarepta Therapeutics (NASDAQ:SRPT) has announced a public offering of 6,172,840 shares at $81.00 per share, aiming for gross proceeds of approximately $500 million. Underwriters have a 30-day option to acquire an additional 925,926 shares. Proceeds will primarily fund clinical trials, commercialization, and business development activities. The offering is expected to close around October 18, 2021, pending customary conditions. Notably, the shares are offered under an effective shelf registration statement filed with the SEC.
Sarepta Therapeutics (NASDAQ:SRPT) reported preliminary Q3 2021 financial results, projecting net product revenues of approximately $166.9 million, a significant increase from $121.4 million in Q3 2020. As of September 30, 2021, the company reported $1.6 billion in cash and investments, down from $1.9 billion at the end of 2020. The results are preliminary, and actual results may vary as they have not yet been finalized or reviewed by independent auditors.
Sarepta Therapeutics (Nasdaq: SRPT) announced a public offering of $500 million in common stock, with an additional $75 million option for underwriters. The proceeds will finance clinical trials, commercialization, and business development, including potential acquisitions. Goldman Sachs, J.P. Morgan, Morgan Stanley, and Credit Suisse are the underwriters. The offering is conducted under an effective shelf registration statement filed with the SEC. A preliminary prospectus will detail the terms.
Sarepta Therapeutics (NASDAQ:SRPT) presented new data from its SRP-9001 program for treating Duchenne muscular dystrophy at 'Micro-dystrophin Day'. Key findings include significant improvements in the North Star Ambulatory Assessment (NSAA) scores: an 8.6-point increase in 4-7 year-olds (Study 101), a 2.9-point increase in 6-7 year-olds (Study 102), and a 3.0-point improvement at six months (Study 103). The EMBARK trial, a pivotal Phase 3 study, aims to enroll 120 patients globally. The safety profile remains consistent, with transient treatment-related adverse events. Sarepta emphasizes the urgency in addressing this degenerative disease.
Sarepta Therapeutics (NASDAQ:SRPT) celebrated the grand opening of its 85,000 square foot Genetic Therapies Center of Excellence in Columbus, Ohio, on October 4, 2021. This facility expands their research capabilities and aims to support their pipeline of genetic medicines, including RNA, gene therapy, and gene editing programs. With 70 employees currently, Sarepta plans to double its workforce by the end of 2022. The center will also enhance collaboration with local partners and bolster Ohio's position in biotechnology.